ProCE Banner Activity

Management Approaches for Diabetic Kidney Disease

Clinical Thought

Improving outcomes in diabetic kidney disease requires effective treatment to control blood glucose, slow progression, and ward off cardiovascular complications. Here’s my take on evidence-based approaches with current and emerging therapies.

Released: July 30, 2021

Expiration: July 29, 2022

No longer available for credit.

Share

Faculty

Vivian A. Fonseca

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Vivian A. Fonseca, MD, FRCP, has disclosed that he has received consulting fees from Abbott, Asahi, AstraZeneca, Bayer, Intarcia, Novo Nordisk, Sanofi, and Takeda; has received funds for research support paid to his institution from Fractyl and Jaguar Gene Therapy; and has ownership interest in Amgen, Bravo, and Mellitus.